BG Medicine Moves from Nasdaq Global Market to Capital Market | GenomeWeb

NEW YORK (GenomeWeb News) – BG Medicine said today that the Nasdaq Listing Qualifications Panel has granted its request to transfer its listing from the Nasdaq Global Market to the Nasdaq Capital Market.

BG requested the transfer, which is effective at open of business today, after failing to meet the $50 million market value of listed securities requirement for listing on the Global Market. The Capital Market requires a company maintain $35 million market value or $2.5 million in stockholders equity.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.